Please use this identifier to cite or link to this item:
|Title:||Serum autoantibodies as biomarkers for early cancer detection||Authors:||Tan, H.T.
|Issue Date:||Dec-2009||Citation:||Tan, H.T., Low, J., Lim, S.G., Chung, M.C.M. (2009-12). Serum autoantibodies as biomarkers for early cancer detection. FEBS Journal 276 (23) : 6880-6904. ScholarBank@NUS Repository. https://doi.org/10.1111/j.1742-4658.2009.07396.x||Abstract:||Autoantibodies against autologus tumor-associated antigens have been detected in the asymptomatic stage of cancer and can thus serve as biomarkers for early cancer diagnosis. Moreover, because autoantibodies are found in sera, they can be screened easily using a noninvasive approach. Consequently, many studies have been initiated to identify novel autoantibodies relevant to various cancer types. To facilitate autoantibody discovery, approaches that allow the simultaneous identification of multiple autoantibodies are preferred. Five such techniques - SEREX, phage display, protein microarray, SERPA and MAPPing - are discussed here. In the second part of this review, we discussed autoantibodies found in the five most common cancers (lung, breast, colorectal, stomach and liver). The discovery of panels of tumor-associated antigens and autoantibody signatures with high sensitivity and specificity would aid in the development of diagnostics, prognostics and therapeutics for cancer patients. © 2009 FEBS.||Source Title:||FEBS Journal||URI:||http://scholarbank.nus.edu.sg/handle/10635/102540||ISSN:||1742464X||DOI:||10.1111/j.1742-4658.2009.07396.x|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Feb 27, 2020
WEB OF SCIENCETM
checked on Feb 20, 2020
checked on Feb 28, 2020
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.